Septerna Inc. (SEPN) is down 63.58 percent during Tuesday's trading, shedding $8.34 to trade at $4.62 after announcing the discontinuation of its Phase 1 clinical trial for SEP-786, a treatment for hypoparathyroidism.
SEPN opened at $4.30 and has ranged between $4.72 and $4.85 throughout the day, with a volume of 4.47 million shares, significantly higher than the average of 312,806. The stock has now fallen to its 52-week low.
The decision follows the observation of two severe adverse events related to elevated bilirubin levels in healthy volunteers, though liver enzyme levels remained unaffected, and the bilirubin levels were reversible.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.